A possible role of neuropeptide Y in depression and stress

Brain Research

Volumn 1314, Issue , 2010, Pages 194-205

  Morales Medina, Julio César ^a,b   Dumont, Yvan ^b   Quirion, Rémi ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b DOUGLAS MENTAL HEALTH UNIVERSITY INSTITUTE   (Canada)

Author keywords

Animal model; Antidepressant; Depression; Mood disorder; Neuropeptide Y; Stress

Indexed keywords

NEUROPEPTIDE Y; NEUROPEPTIDE Y1 RECEPTOR; NEUROPEPTIDE Y2 RECEPTOR; NEUROPEPTIDE Y3 RECEPTOR; NEUROPEPTIDE Y4 RECEPTOR;

AMYGDALOID NUCLEUS; ARTICLE; CEREBELLUM CORTEX; DEPRESSION; DNA POLYMORPHISM; HIPPOCAMPUS; HUMAN; MEMORY; MOOD DISORDER; NONHUMAN; PRIORITY JOURNAL; STRESS;

ANIMALS; BRAIN; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEUROPEPTIDE Y; POLYMORPHISM, GENETIC; RECEPTORS, NEUROPEPTIDE Y; STRESS, PSYCHOLOGICAL;

ANIMALIA; RODENTIA;

EID: 75149114515     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2009.09.077     Document Type: Article

References (128)

1. [APA]. Diagnostic and Statistical Manual of Mental Disorders, Vol. (1994), American Psychiatric Association, Washington, DC
2. Antonijevic I.A., Murck H., Bohlhalter S., Frieboes R.M., Holsboer F., and Steiger A. Neuropeptide Y promotes sleep and inhibits ACTH and cortisol release in young men. Neuropharmacology 39 (2000) 1474-1481
3. Asakawa A., Inui A., Ueno N., Fujimiya M., Fujino M.A., and Kasuga M. Mouse pancreatic polypeptide modulates food intake, while not influencing anxiety in mice. Peptides 20 (1999) 1445-1448
4. Asakawa A., Inui A., Yuzuriha H., Ueno N., Katsuura G., Fujimiya M., Fujino M.A., Niijima A., Meguid M.M., and Kasuga M. Characterization of the effects of pancreatic polypeptide in the regulation of energy balance. Gastroenterology 124 (2003) 1325-1336
5. Bannon A.W., Seda J., Carmouche M., Francis J.M., Norman M.H., Karbon B., and McCaleb M.L. Behavioral characterization of neuropeptide Y knockout mice. Brain Res. 868 (2000) 79-87
6. Berlim M.T., Fleck M.P., and Turecki G. Current trends in the assessment and somatic treatment of resistant/refractory major depression: an overview. Ann. Med. 40 (2008) 149-159
7. Caberlotto L., and Hurd Y.L. Reduced neuropeptide Y mRNA expression in the prefrontal cortex of subjects with bipolar disorder. NeuroReport 10 (1999) 1747-1750
8. Caberlotto L., and Hurd Y.L. Neuropeptide Y Y(1) and Y(2) receptor mRNA expression in the prefrontal cortex of psychiatric subjects. Relationship of Y(2) subtype to suicidal behavior. Neuropsychopharmacology 25 (2001) 91-97
9. 1 binding sites in the Flinders sensitive line rats, a genetic animal model of depression. Neurosci. Lett. 265 (1999) 191-194
10. Cabib S., and Puglisi-Allegra S. Stress, depression and the mesolimbic dopamine system. Psychopharmacology (Berl) 128 (1996) 331-342
11. 5 receptor increases food intake in rats. J. Biol. Chem. 275 (2000) 36043-36048
12. Cador M., Ahmed S.H., Koob G.F., Le Moal M., and Stinus L. Corticotropin-releasing factor induces a place aversion independent of its neuroendocrine role. Brain Res. 597 (1992) 304-309
13. Carvajal C.C., Vercauteren F., Dumont Y., Michalkiewicz M., and Quirion R. Aged neuropeptide Y transgenic rats are resistant to acute stress but maintain spatial and non-spatial learning. Behav. Brain Res. 153 (2004) 471-480
14. 2 knockout mice. J. Mol. Neurosci. 28 (2006) 239-245
15. Castaneda A.E., Tuulio-Henriksson A., Marttunen M., Suvisaari J., and Lonnqvist J. A review on cognitive impairments in depressive and anxiety disorders with a focus on young adults. J. Affect. Disord. 106 (2008) 1-27
16. 1 receptor. Neurosci. Biobehav. Rev. 29 (2005) 113-123
17. Cotton C.H., Flint J., and Campbell T.G. Is there an association between NPY and neuroticism?. Nature 458 (2009) E6 discussion E7
18. Cryan J.F., Page M.E., and Lucki I. Differential behavioral effects of the antidepressants reboxetine, fluoxetine, and moclobemide in a modified forced swim test following chronic treatment. Psychopharmacology (Berl) 182 (2005) 335-344
19. Czermak C., Hauger R., Drevets W.C., Luckenbaugh D.A., Geraci M., Charney D.S., and Neumeister A. Plasma NPY concentrations during tryptophan and sham depletion in medication-free patients with remitted depression. J. Affect. Disord. 110 (2008) 277-281
20. D'Sa C., and Duman R.S. Antidepressants and neuroplasticity. Bipolar Disord. 4 (2002) 183-194
21. de Kloet E.R., de Jong I.E., and Oitzl M.S. Neuropharmacology of glucocorticoids: focus on emotion, cognition and cocaine. Eur. J. Pharmacol. 585 (2008) 473-482
22. de Lange R.P., Wiegant V.M., and Stam R. Altered neuropeptide Y and neurokinin messenger RNA expression and receptor binding in stress-sensitised rats. Brain Res. 1212 (2008) 35-47
23. Detera-Wadleigh S.D., de Miguel C., Berrettini W.H., DeLisi L.E., Goldin L.R., and Gershon E.S. Neuropeptide gene polymorphisms in affective disorder and schizophrenia. J. Psychiatr. Res. 21 (1987) 581-587
24. Duman R.S. Depression: a case of neuronal life and death?. Biol. Psychiatry 56 (2004) 140-145
25. Dumont Y., and Quirion R. An overview of neuropeptide Y: pharmacology to molecular biology and receptor localization. EXS (2006) 7-11
26. 5 receptors in rodents, guinea pig, and primates brains. J. Comp. Neurol. 402 (1998) 372-384
27. Dumont Y., Jacques D., St-Pierre J., Tong Y., Parker R., Herzog H., and Quirion R. Neuropeptide Y, peptide YY and pancreatic polypeptide receptor proteins and mRNAs in mammalian brain. In: Bjornebekk A., and Hokfelt T. (Eds). Peptide Receptors, Part 1 16 (2000), Elsevier Science B.V., Amsterdam 375-475
28. Dumont Y., Morales-Medina J.C., and Quirion R. Neuropeptide Y and its role in anxiety-related disorders. In: Shioda S., Homma I., and Kato N. (Eds). Transmitters and Modulators in Health and Disease (2009), Springer, Kato Bunmeisha 51-82 Vol.
29. Erickson K., Drevets W., and Schulkin J. Glucocorticoid regulation of diverse cognitive functions in normal and pathological emotional states. Neurosci. Biobehav. Rev. 27 (2003) 233-246
30. 5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell. Metab. 4 (2006) 275-282
31. Flood J.F., Hernandez E.N., and Morley J.E. Modulation of memory processing by neuropeptide Y. Brain Res. 421 (1987) 280-290
32. Frisch C., Hanke J., Kleineruschkamp S., Roske S., Kaaden S., Elger C.E., Schramm J., Yilmazer-Hanke D.M., and Helmstaedter C. Positive correlation between the density of neuropeptide Y positive neurons in the amygdala and parameters of self-reported anxiety and depression in mesiotemporal lobe epilepsy patients. Biol. Psychiatry. 66 (2009) 433-440
33. 2 receptor binding in NPY knock out mice does not result in increased receptor function. Peptides 28 (2007) 241-249
34. Gjerris A., Widerlov E., Werdelin L., and Ekman R. Cerebrospinal fluid concentrations of neuropeptide Y in depressed patients and in controls. J. Psychiatry Neurosci. 17 (1992) 23-27
35. 2 receptors: relation to anxiolytic-like phenotype. Behav. Brain Res. 169 (2006) 325-334
36. Hashimoto H., Onishi H., Koide S., Kai T., and Yamagami S. Plasma neuropeptide Y in patients with major depressive disorder. Neurosci. Lett. 216 (1996) 57-60
37. Heilig M. The NPY system in stress, anxiety and depression. Neuropeptides 38 (2004) 213-224
38. Heilig M., Soderpalm B., Engel J.A., and Widerlov E. Centrally administered neuropeptide Y (NPY) produces anxiolytic-like effects in animal anxiety models. Psychopharmacology (Berl) 98 (1989) 524-529
39. Heilig M., Zachrisson O., Thorsell A., Ehnvall A., Mottagui-Tabar S., Sjogren M., Asberg M., Ekman R., Wahlestedt C., and Agren H. Decreased cerebrospinal fluid neuropeptide Y (NPY) in patients with treatment refractory unipolar major depression: preliminary evidence for association with preproNPY gene polymorphism. J. Psychiatr. Res. 38 (2004) 113-121
40. Heinrichs S.C., and Koob G.F. Corticotropin-releasing factor in brain: a role in activation, arousal, and affect regulation. J. Pharmacol. Exp. Ther. 311 (2004) 427-440
41. 5 receptor subclass. World J. Gastroenterol. 14 (2008) 6312-6317
42. Hou C., Jia F., Liu Y., and Li L. CSF serotonin, 5-hydroxyindolacetic acid and neuropeptide Y levels in severe major depressive disorder. Brain Res. 1095 (2006) 154-158
43. Irwin M., Brown M., Patterson T., Hauger R., Mascovich A., and Grant I. Neuropeptide Y and natural killer cell activity: findings in depression and Alzheimer caregiver stress. FASEB J. 5 (1991) 3100-3107
44. 1 receptor. Hippocampus 17 (2007) 271-280
45. Jimenez-Vasquez P.A., Mathe A.A., Thomas J.D., Riley E.P., and Ehlers C.L. Early maternal separation alters neuropeptide Y concentrations in selected brain regions in adult rats. Brain Res. Dev. Brain Res. 131 (2001) 149-152
46. Kallio J., Pesonen U., Kaipio K., Karvonen M.K., Jaakkola U., Heinonen O.J., Uusitupa M.I., and Koulu M. Altered intracellular processing and release of neuropeptide Y due to leucine 7 to proline 7 polymorphism in the signal peptide of preproneuropeptide Y in humans. FASEB J. 15 (2001) 1242-1244
47. Karl T., and Herzog H. Behavioral profiling of NPY in aggression and neuropsychiatric diseases. Peptides 28 (2007) 326-333
48. 1 receptor deficiency on motor activity, exploration, and anxiety. Behav. Brain Res. 167 (2006) 87-93
49. 1 receptor subtype is necessary for the anxiolytic-like effects of neuropeptide Y, but not the antidepressant-like effects of fluoxetine, in mice. Psychopharmacology (Berl) 195 (2008) 547-557
50. Kask A., Vasar E., Heidmets L.T., Allikmets L., and Wikberg J.E. Neuropeptide Y Y(5) receptor antagonist CGP71683A: the effects on food intake and anxiety-related behavior in the rat. Eur. J. Pharmacol. 414 (2001) 215-224
51. Kask A., Harro J., von Horsten S., Redrobe J.P., Dumont Y., and Quirion R. The neurocircuitry and receptor subtypes mediating anxiolytic-like effects of neuropeptide Y. Neurosci. Biobehav. Rev. 26 (2002) 259-283
52. King P.J., Widdowson P.S., Doods H.N., and Williams G. Regulation of neuropeptide Y release by neuropeptide Y receptor ligands and calcium channel antagonists in hypothalamic slices. J. Neurochem. 73 (1999) 641-646
53. King P.J., Williams G., Doods H., and Widdowson P.S. Effect of a selective neuropeptide Y Y(2) receptor antagonist, BIIE0246 on neuropeptide Y release. Eur. J. Pharmacol. 396 (2000) R1-R3
54. Kuromitsu J., Yokoi A., Kawai T., Nagasu T., Aizawa T., Haga S., and Ikeda K. Reduced neuropeptide Y mRNA levels in the frontal cortex of people with schizophrenia and bipolar disorder. Brain Res. Gene Expr. Patterns 1 (2001) 17-21
55. 5 receptor. Physiol. Behav. 97 (2009) 91-97
56. Larhammar D., and Salaneck E. Molecular evolution of NPY receptor subtypes. Neuropeptides 38 (2004) 141-151
57. Lindberg C., Koefoed P., Hansen E.S., Bolwig T.G., Rehfeld J.F., Mellerup E., Jorgensen O.S., Kessing L.V., Werge T., Haugbol S., Wang A.G., and Woldbye D.P. No association between the -399 C > T polymorphism of the neuropeptide Y gene and schizophrenia, unipolar depression or panic disorder in a Danish population. Acta Psychiatr. Scand. 113 (2006) 54-58
58. Lupien S.J., McEwen B.S., Gunnar M.R., and Heim C. Effects of stress throughout the lifespan on the brain, behaviour and cognition. Nat. Rev., Neurosci. 10 (2009) 434-445
59. Manji H.K., Drevets W.C., and Charney D.S. The cellular neurobiology of depression. Nat. Med. 7 (2001) 541-547
60. Mann J.J. Neurobiology of suicidal behaviour. Nat. Rev., Neurosci. 4 (2003) 819-828
61. Mann J.J., Oquendo M., Underwood M.D., and Arango V. The neurobiology of suicide risk: a review for the clinician. J. Clin. Psychiatry 60 Suppl. 2 (1999) 7-11 discussion 18-20, 113-6
62. 5 neuropeptide Y receptor in feeding and obesity. Nat. Med. 4 (1998) 718-721
63. Merikangas K.R., Chakravarti A., Moldin S.O., Araj H., Blangero J.C., Burmeister M., Crabbe Jr. J., Depaulo Jr. J.R., Foulks E., Freimer N.B., Koretz D.S., Lichtenstein W., Mignot E., Reiss A.L., Risch N.J., and Takahashi J.S. Future of genetics of mood disorders research. Biol. Psychiatry 52 (2002) 457-477
64. Mesotten D., Vanhorebeek I., and Van den Berghe G. The altered adrenal axis and treatment with glucocorticoids during critical illness. Nat. Clin. Pract. Endocrinol. Metab. 4 (2008) 496-505
65. Michel M.C., Beck-Sickinger A., Cox H., Doods H.N., Herzog H., Larhammar D., Quirion R., Schwartz T., and Westfall T. XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol. Rev. 50 (1998) 143-150
66. Mitra R., and Sapolsky R.M. Acute corticosterone treatment is sufficient to induce anxiety and amygdaloid dendritic hypertrophy. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 5573-5578
67. 2 receptors reverse behavioral despairs by increasing neurogenesis. 5th Symposium Peptide Receptors and Kinin (2009)
68. Morales-Medina J.C., Sanchez F., Flores G., Dumont Y., and Quirion R. Morphological reorganization after repeated corticosterone administration in the hippocampus, nucleus accumbens and amygdala in the rat. J. Chem. Neuroanat. 38 (2009) 266-272
69. Morgan III C.A., Wang S., Southwick S.M., Rasmusson A., Hazlett G., Hauger R.L., and Charney D.S. Plasma neuropeptide-Y concentrations in humans exposed to military survival training. Biol. Psychiatry 47 (2000) 902-909
70. Morgan III C.A., Wang S., Rasmusson A., Hazlett G., Anderson G., and Charney D.S. Relationship among plasma cortisol, catecholamines, neuropeptide Y, and human performance during exposure to uncontrollable stress. Psychosom. Med. 63 (2001) 412-422
71. Morgan III C.A., Rasmusson A.M., Wang S., Hoyt G., Hauger R.L., and Hazlett G. Neuropeptide-Y, cortisol, and subjective distress in humans exposed to acute stress: replication and extension of previous report. Biol. Psychiatry 52 (2002) 136-142
72. Murray C.J., and Lopez A.D. Evidence-based health policy-lessons from the Global Burden of Disease Study. Science 274 (1996) 740-743
73. Nestler E.J., Gould E., Manji H., Buncan M., Duman R.S., Greshenfeld H.K., Hen R., Koester S., Lederhendler I., Meaney M., Robbins T., Winsky L., and Zalcman S. Preclinical models: status of basic research in depression. Biol. Psychiatry 52 (2002) 503-528
74. Nikisch G., Agren H., Eap C.B., Czernik A., Baumann P., and Mathe A.A. Neuropeptide Y and corticotropin-releasing hormone in CSF mark response to antidepressive treatment with citalopram. Int. J. Neuropsychopharmacol. 8 (2005) 403-410
75. Nikisch G., and Mathe A.A. CSF monoamine metabolites and neuropeptides in depressed patients before and after electroconvulsive therapy. Eur. Psychiatry 23 (2008) 356-359
76. Nilsson C., Karlsson G., Blennow K., Heilig M., and Ekman R. Differences in the neuropeptide Y-like immunoreactivity of the plasma and platelets of human volunteers and depressed patients. Peptides 17 (1996) 359-362
77. Olsson A., Regnell G., Traskman-Bendz L., Ekman R., and Westrin A. Cerebrospinal neuropeptide Y and substance P in suicide attempters during long-term antidepressant treatment. Eur. Neuropsychopharmacol. 14 (2004) 479-485
78. Ordway G.A., Stockmeier C.A., Meltzer H.Y., Overholser J.C., Jaconetta S., and Widdowson P.S. Neuropeptide Y in frontal cortex is not altered in major depression. J. Neurochem. 65 (1995) 1646-1650
79. Page M.E., Detke M.J., Dalvi A., Kirby L.G., and Lucki I. Serotonergic mediation of the effects of fluoxetine, but not desipramine, in the rat forced swimming test. Psychopharmacology (Berl) 147 (1999) 162-167
80. 2 receptors in the effects of immune stress on emotional, locomotor and social behavior of mice. Neuropharmacology 55 (2008) 117-126
81. 4 receptor knockout mice. Genes Brain Behav. 7 (2008) 532-542
82. 1 receptor knockout mice. J. Psychopharmacol. doi:10.1177/0269881109104851.
83. 1 receptor. Nat. Med. 4 (1998) 722-726
84. Pernow J., Lundberg J.M., Kaijser L., Hjemdahl P., Theodorsson-Norheim E., Martinsson A., and Pernow B. Plasma neuropeptide Y-like immunoreactivity and catecholamines during various degrees of sympathetic activation in man. Clin. Physiol. 6 (1986) 561-578
85. Price M.L., Kirby L.G., Valentino R.J., and Lucki I. Evidence for corticotropin-releasing factor regulation of serotonin in the lateral septum during acute swim stress: adaptation produced by repeated swimming. Psychopharmacology (Berl) 162 (2002) 406-414
86. 2+ entry. J. Neurosci. 17 (1997) 8169-8177
87. 1 receptor subtype mediates NPY-induced antidepressant-like activity in the mouse forced swimming test. Neuropsychopharmacology 26 (2002) 615-624
88. 2 receptor knockout mice in two animal models of learning and memory processing. J. Mol. Neurosc. 22 (2003) 121-128
89. 2 receptor knockout mice. Behav. Brain Res. 141 (2003) 251-255
90. Redrobe J.P., Dumont Y., Fournier A., Baker G.B., and Quirion R. Role of serotonin (5-HT) in the antidepressant-like properties of neuropeptide Y (NPY) in the mouse forced swim test. Peptides 26 (2005) 1394-1400
91. Roy A. Neuropeptides in relation to suicidal behavior in depression. Neuropsychobiology 28 (1993) 184-186
92. Ruohonen S.T., Savontaus E., Rinne P., Rosmaninho-Salgado J., Cavadas C., Ruskoaho H., Koulu M., and Pesonen U. Stress-induced hypertension and increased sympathetic activity in mice overexpressing neuropeptide Y in noradrenergic neurons. Neuroendocrinology 89 (2009) 351-360
93. Sahay A., and Hen R. Adult hippocampal neurogenesis in depression. Nat. Neurosci. 10 (2007) 1110-1115
94. 2 receptors in body weight regulation revealed in conditional knockout mice. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 8938-8943
95. Sajdyk T.J., Schober D.A., and Gehlert D.R. Neuropeptide Y receptor subtypes in the basolateral nucleus of the amygdala modulate anxiogenic responses in rats. Neuropharmacology 43 (2002) 1165-1172
96. Sajdyk T.J., Fitz S.D., and Shekhar A. The role of neuropeptide Y in the amygdala on corticotropin-releasing factor receptor-mediated behavioral stress responses in the rat. Stress 9 (2006) 21-28
97. Sajdyk T.J., Johnson P.L., Leitermann R.J., Fitz S.D., Dietrich A., Morin M., Gehlert D.R., Urban J.H., and Shekhar A. Neuropeptide Y in the amygdala induces long-term resilience to stress-induced reductions in social responses but not hypothalamic-adrenal-pituitary axis activity or hyperthermia. J. Neurosci. 28 (2008) 893-903
98. Sapolsky R.M. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch. Gen. Psychiatry 57 (2000) 925-935
99. Schmidt M.V., Liebl C., Sterlemann V., Ganea K., Hartmann J., Harbich D., Alam S., and Muller M.B. Neuropeptide Y mediates the initial hypothalamic-pituitary-adrenal response to maternal separation in the neonatal mouse. J. Endocrinol. 197 (2008) 421-427
100. Schorscher-Petcu A., Austin J.S., Mogil J.S., and Quirion R. Role of central calcitonin gene-related peptide (CGRP) in locomotor and anxiety- and depression-like behaviors in two mouse strains exhibiting a CGRP-dependent difference in thermal pain sensitivity. J. Mol. Neurosci. 39 (2009) 125-136
101. Sjoholm L.K., Melas P.A., Forsell Y., and Lavebratt C. PreproNPY Pro7 protects against depression despite exposure to environmental risk factors. J. Affect. Disord. 118 (2009) 124-130
102. Song C., Earley B., and Leonard B.E. The effects of central administration of neuropeptide Y on behavior, neurotransmitter, and immune functions in the olfactory bulbectomized rat model of depression. Brain Behav. Immun. 10 (1996) 1-16
103. 5 receptors in anxiety and sedation. J. Neurosci. Res. 77 (2004) 723-729
104. Stogner K.A., and Holmes P.V. Neuropeptide-Y exerts antidepressant-like effects in the forced swim test in rats. Eur. J. Pharmacol. 387 (2000) R9-10
105. 4 receptor knockout mice. Neuroscience 158 (2009) 1717-1730
106. Tatemoto K. Neuropeptide Y: complete amino acid sequence of the brain peptide. Proc. Natl. Acad. Sci. U. S. A. 79 (1982) 5485-5489
107. Tatemoto K., Carlquist M., and Mutt V. Neuropeptide Y-a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature 296 (1982) 659-660
108. Thakker-Varia S., and Alder J. Neuropeptides in depression: role of VGF. Behav. Brain Res. 197 (2009) 262-278
109. Thorsell A., Svensson P., Wiklund L., Sommer W., Ekman R., and Heilig M. Suppressed neuropeptide Y (NPY) mRNA in rat amygdala following restraint stress. Regul. Pept. 75-76 (1998) 247-254
110. Thorsell A., Carlsson K., Ekman R., and Heilig M. Behavioral and endocrine adaptation, and up-regulation of NPY expression in rat amygdala following repeated restraint stress. NeuroReport 10 (1999) 3003-3007
111. Thorsell A., Michalkiewicz M., Dumont Y., Quirion R., Caberlotto L., Rimondini R., Mathe A.A., and Heilig M. Behavioral insensitivity to restraint stress, absent fear suppression of behavior and impaired spatial learning in transgenic rats with hippocampal neuropeptide Y overexpression. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 12852-12857
112. Trivedi P.G., Yu H., Trumbauer M., Chen H., Van der Ploeg L.H., and Guan X. Differential regulation of neuropeptide Y receptors in the brains of NPY knock-out mice. Peptides 22 (2001) 395-403
113. 2 receptors. Eur. J. Neurosci. 18 (2003) 143-148
114. Ueno N., Asakawa A., Satoh Y., and Inui A. Increased circulating cholecystokinin contributes to anorexia and anxiety behavior in mice overexpressing pancreatic polypeptide. Regul. Pept. 141 (2007) 8-11
115. Ustun T.B., Ayuso-Mateos J.L., Chatterji S., Mathers C., and Murray C.J. Global burden of depressive disorders in the year 2000. Br. J. Psychiatry 184 (2004) 386-392
116. 5 receptor antagonist Lu AA33810 [N-[[trans-4-[(4,5-dihydro[1]benzothiepino[5,4-d]thiazol-2-yl)amino]cycloh exyl]methyl]-methanesulfonamide] exerts anxiolytic- and antidepressant-like effects in rat models of stress sensitivity. J. Pharmacol. Exp. Ther. 328 (2009) 900-911
117. Weiser T., Wieland H.A., and Doods H.N. Effects of the neuropeptide Y Y(2) receptor antagonist BIIE0246 on presynaptic inhibition by neuropeptide Y in rat hippocampal slices. Eur. J. Pharmacol. 404 (2000) 133-136
118. Westrin A., Engstom G., Ekman R., and Traskman-Bendz L. Correlations between plasma-neuropeptides and temperament dimensions differ between suicidal patients and healthy controls. J. Affect. Disord. 49 (1998) 45-54
119. Westrin A., Ekman R., and Traskman-Bendz L. Alterations of corticotropin releasing hormone (CRH) and neuropeptide Y (NPY) plasma levels in mood disorder patients with a recent suicide attempt. Eur. Neuropsychopharmacol. 9 (1999) 205-211
120. Westrin A., Ekman R., and Traskman-Bendz L. Alterations of corticotropin releasing hormone (CRH) and neuropeptide Y (NPY) plasma levels in mood disorder patients with a recent suicide attempt. Eur. Neuropsychopharmacol. 9 (1999) 205-211
121. Widdowson P.S., Ordway G.A., and Halaris A.E. Reduced neuropeptide Y concentrations in suicide brain. J. Neurochem. 59 (1992) 73-80
122. Widerlov E., Heilig M., Ekman R., and Wahlestedt C. Possible relationship between neuropeptide Y (NPY) and major depression-evidence from human and animal studies Nordic. J. Psychiatry 42 (1988) 131-137
123. Widerlov E., Lindstrom L.H., Wahlestedt C., and Ekman R. Neuropeptide Y and peptide YY as possible cerebrospinal fluid markers for major depression and schizophrenia, respectively. J. Psychiatr. Res. 22 (1988) 69-79
124. 2-receptors in distinct mouse forebrain areas. Neuroscience 136 (2005) 241-250
125. Zhou Z., Zhu G., Hariri A.R., Enoch M.A., Scott D., Sinha R., Virkkunen M., Mash D.C., Lipsky R.H., Hu X.Z., Hodgkinson C.A., Xu K., Buzas B., Yuan Q., Shen P.H., Ferrell R.E., Manuck S.B., Brown S.M., Hauger R.L., Stohler C.S., Zubieta J.K., and Goldman D. Genetic variation in human NPY expression affects stress response and emotion. Nature 452 (2008) 997-1001
126. Zobel A.W., Nickel T., Kunzel H.E., Ackl N., Sonntag A., Ising M., and Holsboer F. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J. Psychiatr. Res. 34 (2000) 171-181
127. Zukowska-Grojec Z., and Vaz A.C. Role of neuropeptide Y (NPY) in cardiovascular responses to stress. Synapse 2 (1988) 293-298
128. Zukowska-Grojec Z., Konarska M., and McCarty R. Differential plasma catecholamine and neuropeptide Y responses to acute stress in rats. Life Sci. 42 (1988) 1615-1624